These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19995392)

  • 1. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis.
    Berneman ZN; Anguille S; Van Marck V; Schroyens WA; Van Tendeloo VF
    Br J Haematol; 2010 Apr; 149(1):152-5. PubMed ID: 19995392
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
    Dagorne A; Douet-Guilbert N; Quintin-Roue I; Guillerm G; Couturier MA; Berthou C; Ianotto JC
    Ann Hematol; 2013 Mar; 92(3):407-9. PubMed ID: 22941306
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
    Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ
    Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
    Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
    J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia.
    Lin Y; Lin R; Zhou G; Liu Y; Dong W; Cao Y; Xie X; Gu W
    J Int Med Res; 2019 Feb; 47(2):1064-1071. PubMed ID: 30616420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).
    Ianotto JC; Kiladjian JJ; Demory JL; Roy L; Boyer F; Rey J; Dupriez B; Berthou C; Abgrall JF
    Br J Haematol; 2009 Jul; 146(2):223-5. PubMed ID: 19545286
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Spohr M; Diehl V; Zankovich R; Niederle N; Leder LD
    Br J Haematol; 2000 Jan; 108(1):64-71. PubMed ID: 10651725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
    Quintás-Cardama A; Verstovsek S
    Leuk Lymphoma; 2007 Mar; 48(3):445-6. PubMed ID: 17454579
    [No Abstract]   [Full Text] [Related]  

  • 10. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
    Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute promyelocytic leukemia with secondary myelofibrosis -- case report and review of the literature.
    Dutta P; Hasan S; Bhattacharyya J; Kumar R; Mahapatra M; Saxena R; Tyagi S; Sazawal S; Pati HP
    Am J Hematol; 2006 Jun; 81(6):476-7. PubMed ID: 16680747
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute myelofibrosis: response to recombinant human interferon alpha-2a.
    List AF; Kummet TD; Kerr DM
    Leuk Res; 1990; 14(4):321-6. PubMed ID: 2332985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon-α2b for local control of Langerhans cell sarcoma.
    Ishitsuka Y; Iwamoto K; Oya K; Nakamura Y; Watanabe R; Okiyama N; Fujisawa Y; Fujimoto M
    Eur J Dermatol; 2018 Dec; 28(6):835-836. PubMed ID: 30355544
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
    Verger E; Rattarittamrong E; Letort G; Raffoux E; Cassinat B; Kiladjian JJ
    Leuk Lymphoma; 2017 Mar; 58(3):749-751. PubMed ID: 27562925
    [No Abstract]   [Full Text] [Related]  

  • 15. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
    Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
    Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient.
    McSweeney EN; Worman CP; Tsakona CP; Jewel AP; Hoffbrand AV; Milligan DW; Burnett AK; Lewis ML; Goldstone AH
    Acta Haematol; 1993; 89(1):1-5. PubMed ID: 8480480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute leukemia with myelofibrosis].
    Zittoun R; Diébold J; Gorin NC
    Nouv Rev Fr Hematol; 1972; 12(2):229-40. PubMed ID: 4264616
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon.
    Fujimura T; Okuyama R; Hashimoto A; Watanabe H; Nakagawa S; Tagami H; Aiba S
    Acta Derm Venereol; 2006; 86(2):161-2. PubMed ID: 16648924
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transformation of myelofibrosis into acute myelogenous leukemia (M0) with multiple tumor emboli].
    Ishizuka Y; Yokota A; Shiga T; Sato J; Oh H; Saitoh Y
    Rinsho Ketsueki; 1998 Aug; 39(8):617-20. PubMed ID: 9785983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.